Published in J Clin Invest on April 15, 1998
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest (1999) 1.85
Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res (2009) 1.80
Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res (2008) 1.26
Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Hum Genet (2006) 0.97
Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol (2008) 0.94
Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner. J Biol Chem (2007) 0.94
Expression of the human apoE2 isoform in adipocytes: altered cellular processing and impaired adipocyte lipogenesis. J Lipid Res (2011) 0.85
Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis. Int J Oncol (2013) 0.82
Apolipoprotein E4 domain interaction accelerates diet-induced atherosclerosis in hypomorphic Arg-61 apoe mice. Arterioscler Thromb Vasc Biol (2012) 0.82
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein. Cardiol Res Pract (2012) 0.78
Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammation. J Lipid Res (2012) 0.78
A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. Am J Pathol (1999) 0.78
Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. Am J Cardiol (2013) 0.77
The effect of 17β-estradiol on cholesterol content in human macrophages is influenced by the lipoprotein milieu. J Mol Endocrinol (2011) 0.75
Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Comput Struct Biotechnol J (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A (1976) 6.38
Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis (1988) 6.01
Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet (1985) 3.81
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science (1995) 3.10
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta (1987) 2.90
Genetics of the apolipoprotein E system in man. Am J Hum Genet (1980) 1.94
Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest (1995) 1.73
Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res (1996) 1.73
Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest (1995) 1.72
Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res (1986) 1.50
Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res (1987) 1.49
Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem (1996) 1.37
Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem (1994) 1.29
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet (1997) 1.27
Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J Lipid Res (1994) 1.23
Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol (1996) 1.20
A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res (1987) 1.15
A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A (1994) 1.13
Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest (1995) 1.11
The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun (1994) 1.10
Macrophage free cholesterol content regulates apolipoprotein E synthesis. J Biol Chem (1987) 1.10
Regulation of macrophage apolipoprotein E gene expression by cholesterol. J Lipid Res (1989) 1.10
Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb (1993) 1.06
A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. Nucleic Acids Res (1994) 1.00
Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase. Am J Pathol (1994) 1.00
Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J Biol Chem (1994) 0.99
Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest (1993) 0.95
Cholesteryl esters from oxidized low-density lipoproteins are in vivo rapidly hydrolyzed in rat Kupffer cells and transported to liver parenchymal cells and bile. Hepatology (1994) 0.93
Dysregulation of lipid metabolism in Tangier monocyte-derived macrophages. Arteriosclerosis (1990) 0.91
Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest (1995) 0.90
A quantitative densitometric method for the rapid separation and quantitation of the major tissue and lipoprotein lipids by high-performance thin-layer chromatography. I. Sample preparation, chromatography, and densitometry. J Chromatogr (1984) 0.89
Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol (1996) 0.89
Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. J Biol Chem (1996) 0.87
Post-translational regulation of macrophage apoprotein E production. J Biol Chem (1992) 0.85
Lysosomal degradation and sorting of apolipoprotein E in macrophages. J Lipid Res (1995) 0.81
Plasma apolipoprotein secretion by human monocyte-derived macrophages. Biochim Biophys Acta (1985) 0.76
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 7.04
Comparison of the complete protein sets of worm and yeast: orthology and divergence. Science (1998) 6.28
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis (1983) 2.37
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res (1997) 2.14
High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2001) 2.03
Comparison of transcutaneous and endtidal CO2-monitoring for rigid bronchoscopy during high-frequency jet ventilation. Acta Anaesthesiol Scand (2003) 2.02
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res (1993) 1.85
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol (2001) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood (2001) 1.75
Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem (1990) 1.75
A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A (1991) 1.69
C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J (2000) 1.63
Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function. Genes Dev (1998) 1.58
A novel frameshift mutation in PMP22 accounts for hereditary neuropathy with liability to pressure palsies. Neurology (1997) 1.56
Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol (1996) 1.55
Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb (1994) 1.52
Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry (1975) 1.50
Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem (1997) 1.50
Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study. J Hypertens (1998) 1.48
D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J (1999) 1.48
Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J (2002) 1.47
Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion (2010) 1.45
Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem (1983) 1.45
Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost (1998) 1.43
Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem (2001) 1.43
Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J Biol Chem (2001) 1.43
Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation (1997) 1.43
Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci (Lond) (1998) 1.40
Measurement of prostate-specific antigen: no advantage to ultrasensitive assays? J Natl Cancer Inst (1996) 1.39
[Primary and secondary prevention of coronary heart disease. A position paper of the International Task Force for the Prevention of Coronary Heart Disease]. Dtsch Med Wochenschr (2000) 1.39
Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res (1996) 1.37
Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol (1999) 1.34
Hind III RFLP in the lipoprotein lipase gene, (LPL). Nucleic Acids Res (1987) 1.32
Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem (1990) 1.31
Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem (2001) 1.29
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J (1999) 1.27
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J (1998) 1.26
Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster. J Clin Endocrinol Metab (2000) 1.26
Pst I RFLP close to the LDL receptor gene. Nucleic Acids Res (1986) 1.26
Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia (2011) 1.25
The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. Atherosclerosis (1977) 1.24
The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem (2001) 1.23
Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice. J Biol Chem (1999) 1.21
Sterol carrier protein X is peroxisomal 3-oxoacyl coenzyme A thiolase with intrinsic sterol carrier and lipid transfer activity. J Biol Chem (1994) 1.19
Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol (2000) 1.18
Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med (Berl) (2000) 1.18
The LQT syndromes--current status of molecular mechanisms. Z Kardiol (1999) 1.18
Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem (1998) 1.17
Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem (1986) 1.17
Lipid-protein interactions in high density lipoproteins. Proc Natl Acad Sci U S A (1974) 1.17
A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest (1991) 1.16
Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res (1991) 1.16
Religious beliefs in schizophrenia: their relevance for adherence to treatment. Schizophr Bull (2007) 1.15
Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis (1999) 1.15
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest (1991) 1.15
Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes (2000) 1.15
Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver. J Biol Chem (1973) 1.14
Developing the skill of endotracheal intubation: implication for emergency medicine. Acta Anaesthesiol Scand (2011) 1.14
Isolation and characterization of an abnormal high density lipoprotein in Tangier Diesase. J Clin Invest (1977) 1.13
A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A (1994) 1.13
Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer (1998) 1.12
The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins. J Clin Invest (1977) 1.12
McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand (2005) 1.12
Cerebral vasomotor changes in the transient syndrome of headache with neurologic deficits and CSF lymphocytosis (HaNDL). Headache (1997) 1.12
Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res (1999) 1.11
The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun (1994) 1.10
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J (1999) 1.10
The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia (2002) 1.10
Sequential and rapid activation of select caspases during apoptosis of normal intestinal epithelial cells. Am J Physiol (1998) 1.10
Acceleration of reverse cholesterol transport. Curr Opin Cardiol (2000) 1.08
An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest (1996) 1.08
Serum ferritin, transferrin, haptoglobin, and iron in middle- and long-distance runners, elite rowers, and professional racing cyclists. Int J Sports Med (1981) 1.07
Polymorphisms in the apolipoprotein AI-CIII gene complex. Mol Biol Med (1986) 1.07
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.06
The VS catalytic RNA replicates by reverse transcription as a satellite of a retroplasmid. Genes Dev (1995) 1.06
Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation (1999) 1.05
Benign nodular fasciitis originating in Tenon's capsule. Arch Ophthalmol (1966) 1.04
Simplified turbidimetric determination of apolipoproteins A-I, A-II and B using a microtitre method. J Clin Chem Clin Biochem (1988) 1.04
The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab (2001) 1.04